Biotron Ltd (ASX: BIT) Share Price and News
Price
$0.0025
Movement
0.00 (0.0)
as at 23 May - Closed (20 mins delayed)
52 Week Range
$0.002 - $0.066
1 Year Return
-95.28%
Biotron Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
$0.0025
Day Change
0.00 (0.0)
52 Week Range
$0.002 - $0.066
Yesterday's Close
$0.0025
Today's Open
$0.0025
Days Range
$0.0025 - $0.0025
Volume
125,000
Avg. Volume (1 month)
711,361
Turnover
$313
as at 23 May - Closed
Biotron Ltd (ASX: BIT)
Latest News
Share Market News
ALL ORDINARIES finishes higher Thursday: 8 ASX shares you missed
Share Gainers
Why Biotron, Magellan, Nick Scali, & Pinnacle shares are surging higher
Share Gainers
Biotron share price rockets higher on coronavirus testing news
Share Market News
These are the 10 best micro-cap shares over the past year
Share Gainers
Why the Biotron share price surged 30% higher today
Share Market News
HIV treatment hopeful Biotron reveals quarterly results
Share Fallers
Why Aristocrat Leisure Limited is among 4 shares tumbling today
Share Fallers
Why the Biotron Limited share price cratered today
Share Fallers
Why Coles Group Limited (ASX:COL) is among 4 shares rising today
Share Gainers
These small cap ASX shares are ending the week on a high
Share Gainers
These 3 small cap ASX shares are surging higher today
Share Gainers
These small cap ASX shares are on the rise on Monday
BIT ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
23rd May 2025 2025-05-23T10:25:14 | Biotron Investor Webinar | YesNo | 10:25am | 1 | 446k |
2nd May 2025 2025-05-02T13:52:47 | Company Secretary Appointment/Resignation | YesNo | 1:52pm | 1 | 41k |
24th Apr 2025 2025-04-24T09:07:48 | Quarterly Activities/Appendix 4C Cash Flow Report | YesNo | 9:07am | 7 | 358k |
10th Apr 2025 2025-04-10T10:15:34 | Change of Director's Interest Notice | YesNo | 10:15am | 7 | 276k |
8th Apr 2025 2025-04-08T09:07:46 | Application for quotation of securities - BIT | YesNo | 9:07am | 6 | 16k |
8th Apr 2025 2025-04-08T09:06:51 | Rights Issue Closed | YesNo | 9:06am | 2 | 137k |
18th Mar 2025 2025-03-18T11:34:16 | Dispatch of Rights Issue Offer documents | YesNo | 11:34am | 2 | 264k |
13th Mar 2025 2025-03-13T09:32:45 | Update on Rights Issue Timetable | YesNo | 9:32am | 2 | 165k |
13th Mar 2025 2025-03-13T08:31:55 | Update - Proposed issue of securities - BIT | YesNo | 8:31am | 6 | 21k |
12th Mar 2025 2025-03-12T17:23:25 | Replacement Prospectus | YesNo | 5:23pm | 43 | 395k |
About Biotron Ltd
Biotron Ltd is a biotechnology company. It is engaged in the funding and management of intermediate and applied biotechnology research and development projects. Its antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. Geographically, it operates only in Australia through biotechnology segment.
BIT Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
23 May 2025 | $0.00 | $0.00 | 0.00% | 125,000 | $0.00 | $0.00 | $0.00 |
22 May 2025 | $0.00 | $0.00 | 0.00% | 565,000 | $0.00 | $0.00 | $0.00 |
21 May 2025 | $0.00 | $0.00 | 0.00% | 1,266,188 | $0.00 | $0.00 | $0.00 |
20 May 2025 | $0.00 | $0.00 | 0.00% | 920,250 | $0.00 | $0.00 | $0.00 |
19 May 2025 | $0.00 | $0.00 | 0.00% | 2,078,389 | $0.00 | $0.00 | $0.00 |
16 May 2025 | $0.00 | $0.00 | 0.00% | 201,727 | $0.00 | $0.00 | $0.00 |
15 May 2025 | $0.00 | $0.00 | 0.00% | 823,522 | $0.00 | $0.00 | $0.00 |
14 May 2025 | $0.00 | $0.00 | 0.00% | 63,780 | $0.00 | $0.00 | $0.00 |
13 May 2025 | $0.00 | $0.00 | 0.00% | 521,917 | $0.00 | $0.00 | $0.00 |
12 May 2025 | $0.00 | $0.00 | 0.00% | 857,727 | $0.00 | $0.00 | $0.00 |
09 May 2025 | $0.00 | $0.00 | 0.00% | 315,500 | $0.00 | $0.00 | $0.00 |
08 May 2025 | $0.00 | $0.00 | 0.00% | 60,045 | $0.00 | $0.00 | $0.00 |
07 May 2025 | $0.00 | $0.00 | 0.00% | 205,761 | $0.00 | $0.00 | $0.00 |
06 May 2025 | $0.00 | $0.00 | 0.00% | 418,979 | $0.00 | $0.00 | $0.00 |
05 May 2025 | $0.00 | $0.00 | 0.00% | 420,056 | $0.00 | $0.00 | $0.00 |
02 May 2025 | $0.00 | $0.00 | 0.00% | 3,405,849 | $0.00 | $0.00 | $0.00 |
01 May 2025 | $0.00 | $0.00 | 0.00% | 321,000 | $0.00 | $0.00 | $0.00 |
30 Apr 2025 | $0.00 | $0.00 | 0.00% | 458,025 | $0.00 | $0.00 | $0.00 |
29 Apr 2025 | $0.00 | $0.00 | 0.00% | 1,131,399 | $0.00 | $0.00 | $0.00 |
28 Apr 2025 | $0.00 | $0.00 | 0.00% | 341,722 | $0.00 | $0.00 | $0.00 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
08 Apr 2025 | Michael Hoy | Issued | 11,217,353 | $33,652 |
Rights issue.
|
08 Apr 2025 | Robert Thomas | Issued | 4,200,000 | $12,600 |
Rights issue.
|
08 Apr 2025 | Michelle Miller | Issued | 1,800,000 | $5,400 |
Rights issue.
|
08 Apr 2025 | Michelle Miller | Issued | 1,987,500 | $5,962 |
Rights issue.
|
25 Nov 2024 | Michael Hoy | Expiry | 934,780 | $17,760 |
Options expired.
|
25 Nov 2024 | Michelle Miller | Expiry | 315,000 | $5,985 |
Options expired. As per announcement on 28-11-2024
|
25 Nov 2024 | Robert Thomas | Expiry | 268,403 | $5,099 |
Options expired.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Michael J Hoy | Non-Executive DirectorNon-Executive Chairman | Feb 2000 |
Mr Hoy has more than 30 years of corporate experience in Australia, the United Kingdom, USA and Asia. He is Chairman of Lipotek Pty Limited and a former director of John Fairfax Holdings Limited and FXF Trust.
|
Mr Robert Bain Thomas | Non-Executive Director | Mar 2012 |
Mr Thomas has over 35 years of experience in the securities industry, with Potter Partners (now UBS), County NatWest and Citigroup. He is the chairman of Starpharma Holdings Limited and a director of Clarity Pharmaceuticals Limited. He chairs Grahger Securities Pty Ltd and is a director of O'Connell Street Associates Pty Limited.
|
Dr Michelle Miller | Managing Director | Jun 2002 |
Dr Miller has worked for over 25 years in the bioscience industry, with experience in commercial drug development. Her experience includes several years at Johnson & Johnson developing anti-HIV gene therapeutics through preclinical research to clinical trials. She has finance industry experience from time spent as an Investment Manager with a specialist bioscience venture capital fund.
|
Mr Marcelo Mora | Company Secretary | May 2025 |
-
|
Marcelo Mora | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Rookharp Capital Pty Limited | 26,920,201 | 2.98% |
Jey Investment Pty Ltd | 24,240,000 | 2.69% |
Umbiram Pty Ltd <Michael Hoy Superfund A/C> | 11,217,352 | 1.24% |
Fordholm Investments Pty Ltd <Fordholm Super Fund A/C> | 10,300,000 | 1.14% |
Citicorp Nominees Pty Limited | 10,201,698 | 1.13% |
Dr Angela Fay Dulhunty | 10,000,000 | 1.11% |
Dr Huy Tran | 9,699,357 | 1.07% |
Dns Accounting And Law Consultancy Pty Ltd | 8,359,582 | 0.93% |
Attollo Copia Pty Ltd <F A Pires Super Fund A/C> | 7,620,678 | 0.84% |
Pathold No 222 Pty Ltd | 7,600,000 | 0.84% |
Armco Barriers Pty Ltd | 7,550,000 | 0.84% |
Mr William John Dunn | 7,300,000 | 0.81% |
Edstop Pty Limited <Superannuation Fund A/C> | 6,045,906 | 0.67% |
Standby Forty Six Pty Limited | 5,600,000 | 0.62% |
Vicex Holdings Proprietary Limited <Vicex Super A/C> | 5,600,000 | 0.62% |
Scotts A V Pty Ltd <Scotts Acorn Emp S/F A/C> | 4,918,000 | 0.55% |
Mr Travis Paul Gloury | 4,819,355 | 0.53% |
Mr Charles Tollios Panos | 4,338,928 | 0.48% |
Mr Peter James Nightingale | 4,313,884 | 0.48% |
Mr Mark Andrew Peterson | 4,263,157 | 0.48% |